2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here.
Where Will CRISPR Therapeutics Be in 3 Years?
Where Will CRISPR Therapeutics Be in 3 Years?
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost. Despite no Q3 revenue from Casgevy, CRISPR maintains a strong cash position and continues to advance its diverse pipeline, including CAR-T and in-vivo therapies. Vertex's partnership and investment highlight Casgevy's potential, but long-term success hinges on improving treatment processes and securing further drug approvals.
Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?
The mean of analysts' price targets for CRISPR Therapeutics (CRSP) points to a 62.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.41 per share a year ago.
CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average
CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CRSP crossed above the 20-day moving average, suggesting a short-term bullish trend.
CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average
After reaching an important support level, CRISPR Therapeutics AG (CRSP) could be a good stock pick from a technical perspective. CRSP surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
It won't be able to be profitable without hitting its targets for both of these figures.
CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?
On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.
Crispr Therapeutics: Poised For A Major Turnaround
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharmaceuticals has provided significant financial support, experienced leadership, and validation, positioning Crispr for long-term success in the gene-editing space. Crispr's shares are currently undervalued, offering a strong buy opportunity below $50, with incoming revenue from Casgevy and a promising drug pipeline.
